Telehealth IOP: The Evidence and the Limits

Before 2020, virtual substance use treatment was a niche modality used in limited rural and specialty settings. During the COVID-19 public health emergency, federal and state regulators allowed near-universal telehealth delivery of substance use care, and many outpatient programs pivoted overnight. The relevant question is no longer whether telehealth IOP exists, it exists and is widely available, but whether it works, and who it works for.

The short answer: for most patients with substance use disorders at the IOP level, outcomes of telehealth IOP are comparable to in-person IOP on the metrics that matter most (retention, substance use reduction, quality of life), provided the program is well-run and the patient has the infrastructure to participate. The longer answer has more nuance.

What telehealth IOP typically looks like

A well-run telehealth IOP replicates the clinical structure of in-person IOP in a video-conference format:

• Group therapy, typically 3 sessions per week of 2 to 3 hours each. Groups are capped (often at 8 to 10 participants) to allow meaningful participation on video.
• Individual therapy, typically weekly, via video.
• Medication management, via telehealth with a prescribing clinician, for patients receiving MOUD, MAUD, or treatment of co-occurring conditions.
• Family sessions, often more easily scheduled via telehealth than in-person.
• Drug testing, via mail-in kits or coordinated at partner laboratories.

The content of a good telehealth IOP, CBT for SUD, relapse prevention, motivational interviewing, co-occurring treatment, is the same as the content of a good in-person IOP. The delivery is different; the clinical curriculum is not.

What the evidence shows

Several studies during and after the pandemic have compared telehealth IOP to in-person IOP:

• Retention is comparable or slightly better in telehealth IOP for most populations studied. The logistical friction of getting to a program 3 evenings per week is a meaningful barrier; removing it improves attendance.
• Substance use outcomes are comparable at 3, 6, and 12 months when matched for clinical acuity and engagement.
• Patient satisfaction is generally higher with telehealth formats, particularly for patients with caregiving responsibilities, transportation barriers, or rural residence.
• Buprenorphine initiation and retention via telehealth have been studied separately and appear to produce outcomes comparable to in-person induction, including for patients with no prior MOUD exposure.

The evidence base is still developing, particularly for specific subpopulations (adolescents, severe co-occurring conditions, opioid use disorder with recent overdose events). The existing evidence supports telehealth IOP as a clinically reasonable option for most patients at the IOP level.

Who telehealth IOP fits well

Patients for whom telehealth IOP is often a strong fit:

• Working adults whose schedules make in-person evening programming difficult or impossible.
• Parents or caregivers who cannot arrange child or elder care for 3 evenings per week.
• Rural patients for whom the nearest in-person IOP is a 45-minute drive or more.
• Patients with mobility issues or disabilities that make regular in-person attendance difficult.
• Patients whose recovery network is geographically distributed (e.g., a partner in another city participating in family sessions).
• Patients with agoraphobia, social anxiety, or PTSD for whom the group therapy container is easier to engage with from a familiar setting.

Who telehealth IOP does not fit well

Patients for whom telehealth IOP is often not sufficient:

• Patients without private space in which to participate in group therapy. Substance use treatment requires candor about sensitive material; a patient joining group from a busy household or a car in a parking lot is at a disadvantage. Programs should screen for this.
• Patients without reliable internet or device access. This is a real barrier, particularly for lower-income patients and patients in specific rural areas.
• Patients with significant cognitive or sensory impairments that make video-based group participation effortful.
• Patients whose substance use is driven by isolation, for whom the in-person element of group therapy is therapeutically important.
• Patients in acute crisis, severe suicidal ideation, acute withdrawal, acute psychosis, who require a higher level of care than IOP regardless of delivery modality.
• Patients who need to get out of the house as part of their recovery structure. Some patients benefit specifically from the routine of leaving home to attend programming; for them, in-person is a feature, not a bug.

The specific buprenorphine and controlled-substance question

Federal regulations on telehealth prescribing of controlled substances, including buprenorphine, have been in flux since 2020.

Under current DEA flexibilities (extended through the end of 2025 with indications of further extension), buprenorphine can be initiated via audio-video telehealth without an in-person visit, with some state-level variation. A patient can have a full induction, stabilization, and maintenance of buprenorphine entirely via telehealth in most jurisdictions, provided local law and the program's own policies allow it.

For methadone, the 2024 SAMHSA final rule expanded telehealth flexibilities but methadone dispensing for opioid use disorder continues to require in-person dosing at an Opioid Treatment Program, with telehealth used for ancillary services (counseling, prescriber visits for comorbidities, case management).

Regulatory status in this area can change. For current federal status, check SAMHSA and DEA guidance. For state-level detail, check the state's Medicaid and professional licensing boards.

How to tell a good telehealth IOP from a weak one

Many programs pivoted to telehealth quickly in 2020 and have stabilized into good clinical programs. Others are effectively group therapy over Zoom without the supporting clinical infrastructure. Questions that separate them:

• What is the clinical curriculum? The answer should reference CBT, MI, relapse prevention, or similar evidence-based approaches, the same standards that apply to in-person programs.
• What is the group size? Beyond 10 to 12 participants on a single video call, meaningful clinical group work becomes difficult.
• Is MOUD/MAUD integrated into the program? If the program is run by counseling staff alone and has no prescriber, it is operating below the standard of care for patients with opioid or alcohol use disorder.
• How is drug testing handled? Reputable programs use mail-in kits or partner labs. Programs that do not drug-test at all during an IOP course are skipping a standard element of care.
• What is the plan when a patient is not in recovery? Well-run programs have clinical pathways for patients who relapse during treatment, not immediate discharge, not policing, but clinical response. A program that discharges patients for positive drug tests is operating below the evidence.
• How are crises handled? Telehealth programs should have written protocols for patient safety concerns that arise during sessions, including warm hand-offs to local emergency services and awareness of the patient's physical location.

For more detail, see Questions to Ask a Program Before You Enroll.

The bottom line

Telehealth IOP is a legitimate, well-evidenced level of care for most patients at the IOP level. It removes access barriers, maintains clinical quality when well-run, and produces outcomes comparable to in-person IOP on the outcomes that matter. It is not a universal fit, some patients do better with the structure and in-person contact of a traditional program, but for the majority of working adults, parents, and geographically dispersed patients, telehealth IOP has made evidence-based structured outpatient care substantially more accessible than it was before 2020.

What to read next

• PHP vs. IOP: What the Difference Actually Is
• Medications for Opioid Use Disorder
• Questions to Ask a Program Before You Enroll